HURA (TuHURA Biosciences) EBIT: $-30.27 Mil (TTM As of Mar. 2026)


HURA TuHURA Biosciences Inc HURA
12 GF Score
Price $2.59
! 1 Warning Sign
View Full Analysis

What is TuHURA Biosciences EBIT?

TuHURA Biosciences HURA +2.57% 12 EBIT is $-30.27 Mil as of Mar. 2026. GuruFocus rates HURA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

TuHURA Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-7.51 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-30.27 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TuHURA Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 was -122.21%. TuHURA Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4,413.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TuHURA Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -18.99%.

TuHURA Biosciences  (NAS:HURA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TuHURA Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-30.12 * ( 1 - 0% )/( (24.653 + 24.638)/ 2 )
=-30.12/24.6455
=-122.21 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=27.353 - 3.998 - ( 3.62 - max(0, 5.919 - 4.621+3.62))
=24.653

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=29.705 - 4.152 - ( 6.298 - max(0, 6.067 - 6.982+6.298))
=24.638

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

TuHURA Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-30.036/( ( (0.685 + max(-5.022, 0)) + (0.676 + max(-5.176, 0)) )/ 2 )
=-30.036/( ( 0.685 + 0.676 )/ 2 )
=-30.036/0.6805
=-4,413.81 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.501) - (3.998 + 0 + 1.525)
=-5.022

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.684) - (4.152 + 0 + 1.708)
=-5.176

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TuHURA Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-30.272/159.373
=-18.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences EBIT Related Terms

TuHURA Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for TuHURA Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences EBIT Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-6.39 -9.37 -29.30 -17.54 -29.43

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.66 -9.52 -7.09 -6.15 -7.51

HURA vs AGEN, CRBP, SPRB: EBIT Comparison

For the Biotechnology subindustry, TuHURA Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TuHURA Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's EV-to-EBIT falls into.


HURA
12GF Score
TuHURA Biosciences Inc HURA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TuHURA Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-30.27 Mil mean?
TuHURA Biosciences (HURA) has a EBIT of $-30.27 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TuHURA Biosciences.
Is TuHURA Biosciences' EBIT too high?
TuHURA Biosciences' current EBIT is $-30.27 Mil. Overall, TuHURA Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TuHURA Biosciences' EBIT compare to AGEN and CRBP?
TuHURA Biosciences' EBIT of $-30.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TuHURA Biosciences. TuHURA Biosciences's current EBIT is $-30.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TuHURA Biosciences stock overvalued right now?
TuHURA Biosciences (HURA) has a current EBIT of $-30.27 Mil. The current EBIT is $-30.27 Mil. TuHURA Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TuHURA Biosciences (HURA), the current EBIT is $-30.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TuHURA Biosciences Business Description

Other Exchanges PL3:Germany
Address 10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
12GF Score

Get the complete analysis for HURA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price